当前位置:主页 > 肿瘤疾病 > 文章内容

NCCN临床实践指南:宫颈癌(2027.V1)

作者:中华医学网发布时间:2026-11-08 15:25浏览: 次

Overview

These NCCN Guidelines cover the evaluation, staging, treatment, surveillance, and supportive care for invasive cervical carcinoma, including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, and rare histologies (e.g., neuroendocrine carcinoma, gastric-type adenocarcinoma, clear cell carcinoma). The guideline applies to patients with newly diagnosed cervical cancer, recurrent disease, and metastatic cervical cancer. It does not cover cervical intraepithelial neoplasia (CIN) or adenocarcinoma in situ (AIS). FIGO 2018 staging is adopted, supplemented by cross-sectional imaging and pathological findings for clinical management.

1. Initial Diagnostic Workup

1.1 Required baseline evaluation

  • History and physical examination, including pelvic exam with colposcopy, biopsy confirmation of malignancy.
  • Histopathology review: subtype, differentiation, lymphovascular space invasion (LVSI), margin status if prior conization.
  • Laboratory testing: CBC, comprehensive metabolic panel, renal function.
  • HPV and p16 testing to support diagnosis when pathology is equivocal.
  • Imaging:
    • Chest CT for all invasive cervical cancer to rule out pulmonary metastases.
    • Pelvic MRI with contrast is preferred for local tumor extent, parametrial invasion, and assessment of vaginal/rectal/bladder involvement.
    • Abdominopelvic contrast-enhanced CT or MRI for nodal and distant evaluation.
    • ¹⁸F-FDG PET‑CT: recommended for FIGO IB3–IVA disease to evaluate nodal and distant spread; optional for selected IB1–IB2 high-risk patients.
  • Cystoscopy, proctoscopy: only when clinical or imaging evidence suggests bladder or rectal invasion.
  • Fertility consultation for patients desiring future pregnancy.

1.2 Biomarker testing (new in 2027.V1)

  • PD‑L1 (CPS) for all patients with locally advanced, recurrent or metastatic cervical cancer.
  • MSI‑H/dMMR testing for all histologic subtypes.
  • NGS panel (including HER2, NTRK, KRAS, etc.) for recurrent/metastatic disease, especially for non-squamous subtypes.
  • HER2 testing by IHC + FISH for gastric-type adenocarcinoma and advanced adenocarcinoma.

2. Staging and Risk Stratification (FIGO 2018)

  • Stage I: Tumor strictly confined to cervix
    • IA1: Invasive carcinoma ≤3 mm depth, ≤7 mm horizontal spread
    • IA2: >3 mm and ≤5 mm depth, ≤7 mm horizontal spread
    • IB1: >5 mm stromal invasion, ≤2 cm tumor
    • IB2: >2 cm and ≤4 cm
    • IB3: >4 cm
  • Stage II: Tumor invades beyond cervix but not to pelvic wall or lower third vagina
    • IIA: No parametrial invasion; IIA1 ≤4 cm, IIA2 >4 cm
    • IIB: Parametrial invasion
  • Stage III: Tumor extends to pelvic sidewall, involves lower third vagina, or causes hydronephrosis/non-functioning kidney
    • IIIA: Lower third vagina
    • IIIB: Pelvic sidewall / hydronephrosis
    • IIIC: Pelvic or para-aortic nodal involvement (IIIC1 pelvic nodes only; IIIC2 para-aortic nodes)
  • Stage IV:
    • IVA: Invades bladder or rectal mucosa
    • IVB: Distant metastases

NCCN note: Nodal positivity (IIIC) is not automatically equivalent to systemic disease; definitive chemoradiation remains primary for IIIC locoregional disease.

3. Treatment for Newly Diagnosed Disease

3.1 Stage IA1

  • No LVSI: Conization (fertility-sparing) or extrafascial hysterectomy.
  • With LVSI: Modified radical hysterectomy + pelvic lymph node dissection; or radical trachelectomy + pelvic node assessment for fertility preservation.
  • Sentinel lymph node mapping (SLN) is preferred over full pelvic lymphadenectomy for low-volume IA1–IB1.

3.2 Stage IA2

Options:

  1. Radical trachelectomy + SLN/pelvic node assessment (fertility-sparing)
  2. Modified radical hysterectomy + pelvic lymph node dissection Adjuvant management based on final pathology.

3.3 Stage IB1 / IB2, selected IIA1 (≤4 cm)

Two main strategies:

  • Fertility preservation: Radical trachelectomy + SLN biopsy/pelvic lymph node assessment. Contraindicated if poor histology, extensive LVSI.
  • Non-fertility: Radical hysterectomy + pelvic lymph node assessment; para-aortic sampling for high-risk features. Postoperative adjuvant risk stratification (Sedlis criteria):
  • Low-risk: No adjuvant therapy.
  • Intermediate risk: Consider adjuvant pelvic radiation (with or without concurrent cisplatin) based on Sedlis.
  • High-risk (positive surgical margins, positive pelvic nodes, parametrial involvement): Adjuvant concurrent chemoradiation (pelvic radiation + cisplatin).

3.4 IB3, IIA2 (>4 cm), IIB–IVA Locally Advanced Cervical Cancer (LACC)

Primary definitive concurrent chemoradiation (CCRT) is preferred standard of care.

  • External beam radiotherapy (EBRT): Pelvic ± para-aortic nodal volume as indicated by PET/CT.
  • Concurrent chemotherapy: Weekly cisplatin 40 mg/m² (preferred). Cisplatin + 5‑FU is an alternative.
  • Image-guided brachytherapy (IGBT) is mandatory boost after EBRT; intracavitary or combined intracavitary/interstitial for bulky/irregular tumors.
  • Surgery after CCRT (planned hysterectomy) is not recommended routinely; only for residual isolated pelvic mass in selected centers.

3.5 Stage IVB (Distant metastatic at diagnosis)

Systemic therapy is primary; local radiotherapy for symptomatic pelvic disease (bleeding, pain, obstruction). Performance status, PD‑L1, MSI status guide regimen selection.

4. Recurrent Cervical Cancer

4.1 Isolated pelvic recurrence (no prior radiation)

  • If resectable: Radical pelvic surgery (exenteration for central recurrence) or definitive CCRT.
  • If unresectable: CCRT.

4.2 Recurrence after prior pelvic radiation

  • Re-irradiation (SBRT / interstitial brachytherapy) only in highly selected cases in specialized centers; high gastrointestinal/genitourinary toxicity.
  • Most patients receive systemic therapy ± palliative local ablation/SBRT for oligometastatic recurrence.
  • Pelvic exenteration may be considered for central isolated recurrence without distant spread and no para-aortic nodal disease.

5. Systemic Therapy for Advanced / Recurrent / Metastatic Cervical Cancer

First-line (for metastatic or persistent disease)

  1. PD‑L1 positive (CPS ≥1): Pembrolizumab + platinum + paclitaxel ± bevacizumab (category 1 preferred).
  2. PD‑L1 negative or CPS <1: Platinum + paclitaxel ± bevacizumab.
  3. Bevacizumab is added for eligible patients with no contraindications (avoid in active bowel fistula, uncontrolled hypertension).
  4. MSI‑H/dMMR: PD‑1 inhibitor monotherapy is acceptable first-line alternative.

Second-line and subsequent lines

  • Options: Pembrolizumab (MSI‑H/dMMR only), dostarlimab, tisotumab vedotin, cabozantinib, lenvatinib + pembrolizumab, paclitaxel, topotecan, gemcitabine, vinorelbine.
  • NTRK fusion positive: Larotrectinib / entrectinib.
  • HER2-amplified adenocarcinoma: Trastuzumab-containing regimens.
  • Neuroendocrine cervical carcinoma: Follow small cell lung cancer-type platinum-etoposide backbone.

Tisotumab vedotin is category 1 for previously treated recurrent/metastatic cervical cancer regardless of PD‑L1 status in 2027.V1 update.

6. Radiotherapy Technical Principles

  • IMRT/VMAT/IGRT preferred to reduce bowel, bladder, bone marrow dose.
  • Brachytherapy: MRI-based planning for cervical cancer; dose prescription to HR‑CTV.
  • Normal tissue constraints: rectum, bladder, sigmoid, small bowel must be strictly constrained.
  • Para-aortic radiation extended field only for confirmed IIIC2 para-aortic nodal disease.

7. Surveillance After Curative Treatment

  • First 2 years: Every 3–6 months: history, pelvic exam, cervical/vaginal cytology + HPV co-testing. Imaging only for symptoms or abnormal exam.
  • Years 3–5: Every 6–12 months.
  • After 5 years: Annual follow-up.
  • Cross-sectional imaging (CT/MRI/PET) is not routine for asymptomatic patients; ordered for suspicious symptoms or exam findings.
  • Symptom education: vaginal bleeding, pelvic pain, leg swelling, weight loss, hematuria, melena.

8. Special Histologies

  • Neuroendocrine carcinoma of cervix: Aggressive, staging with PET‑CT; platinum-etoposide chemotherapy + radiotherapy or surgery for limited disease; poor prognosis.
  • Gastric-type adenocarcinoma: Less responsive to platinum; HER2 testing recommended; surgery preferred for early stage.
  • Clear cell carcinoma: More common in younger patients; management follows squamous/adenocarcinoma framework, higher distant failure risk.

9. Supportive Care and Survivorship

  • Sexual health, vaginal dilator use after pelvic radiation; lymphedema prevention for pelvic nodal dissection.
  • Chemotherapy-induced nausea/vomiting, neutropenia prophylaxis.
  • Bevacizumab monitoring: blood pressure, proteinuria, fistula risk.
  • Fertility preservation discussion before radical surgery or pelvic radiation.
  • Palliative care integration early for metastatic disease.

10. 2027.V1 Key Updates

  1. Tisotumab vedotin upgraded to category 1 for second-line and beyond recurrent/metastatic cervical cancer.
  2. Mandatory NGS recommendation for advanced adenocarcinoma and gastric-type subtype, including HER2.
  3. Refined SLN algorithm: lower threshold for SLN biopsy in IB1–IB2; criteria for skip metastasis risk.
  4. Clarified that routine adjuvant hysterectomy after CCRT for LACC is not recommended outside clinical trials.
  5. Expanded lenvatinib + pembrolizumab as alternative for platinum-refractory disease.
  6. Updated toxicity screening for antibody‑drug conjugates (ocular toxicity for tisotumab vedotin).

Citation

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer Version 2.2027. Available from NCCN.org.